Diagnostic performance of the MelaFind device in a real-life clinical setting

• Verfasst von: Müller-Christmann, Christine [VerfasserIn]
• Verfasst von: Hänßle, Holger [VerfasserIn]
• Titel: Diagnostic performance of the MelaFind device in a real-life clinical setting
• Verf.angabe: Christine Fink, Claudia Jaeger, Katharina Jaeger, Holger A. Haenssle
• E-Jahr: 2017
• Jahr: 23 March 2017
• Umfang: 6 S.
• Fussnoten: Gesehen am 22.08.2019
• Titel Quelle: Enthalten in: Deutsche Dermatologische GesellschaftJournal der Deutschen Dermatologischen Gesellschaft
• Ort Quelle: Berlin : Wiley-Blackwell, 2003
• Jahr Quelle: 2017
• Band/Heft Quelle: 15(2017), 4, Seite 414-419
• ISSN Quelle: 1610-0387
• DOI: doi:10.1111/ddg.13220
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1581018142

Abstract

Background MelaFind is a multispectral computer vision system intended to ­provide additional information on melanocytic lesions suspected of being melanoma by ­objectively assessing their three-dimensional morphology. Objectives Analysis of the diagnostic performance of MelaFind in a real-life clinical setting. Patients and methods In this observational study, 360 pigmented skin lesions (PSL) in 111 patients were assessed by office-based dermatologists using MelaFind. Scores ≥ 2 were considered to be suspicious of malignancy. The decision for surgical excision was left to the discretion of the examining dermatologists. Results MelaFind scores ≥ 2 were observed in 147 of 360 PSL (40.8 %). Of the 107 excised lesions with a MelaFind-score ≥ 2, the diagnosis of melanoma was made in three cases; 53 (49.5 %) lesions proved to be dysplastic nevi. Among all lesions biopsied (n = 113), the sensitivity and specificity of MelaFind was 100 % and 5.5 %, respectively. While a higher specificity of 68.5 % may be assumed with respect to the overall data set (n = 360), this assumption is limited by incomplete follow-up data required to confirm that all non-excised lesions with a score < 2 were actually benign. Conclusion The high sensitivity of MelaFind facilitated the detection of melanoma. The overall specificity and benign-to-malignant ratio of excised lesions were acceptable. These parameters may be improved by using higher cutoff scores for excisional biopsies, and by more vigorously selecting PSL for MelaFind examination.